by mpzzqmvj | May 17, 2021 | Press Releases
– Pivotal Phase 3 study of Trappsol® Cyclo™ for Niemann-Pick Disease Type C (NPC) on track to commence enrollment and dosing in Q2 2021- Company advancing Alzheimer’s Disease Phase 2 asset towards investigational new drug application (IND)...
by mpzzqmvj | May 11, 2021 | Press Releases
Ms. Gorski brings more than two decades of communications and patient advocacy experience serving rare disease communitiesFormerly led global communications and patient advocacy strategies for lysosomal storage disorders at Sanofi Genzyme GAINESVILLE, Fla. –...
by mpzzqmvj | Apr 27, 2021 | Press Releases
Patient enrollment on track to commence in Q2 2021Global clinical protocol agreed with US Food and Drug Administration (FDA) and European MedicinesAgency (EMA)Dual primary objectives agreed; FDA 4-Domain Niemann-Pick disease Type C-Severity Scale (4D-NPC-SS) and EMA...
by mpzzqmvj | Apr 20, 2021 | Press Releases
FDA feedback supports Company’s Phase 2 development strategy for Alzheimer’s disease asset; IND filing on track for H2 2021 GAINESVILLE, Fla. – Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a...
by mpzzqmvj | Mar 25, 2021 | Press Releases
100% of patients who completed the trial improved or remained stable, and 89% met the efficacy outcome measure of improvement in at least 2 domains of the 17-domain NPC Severity Scale Trial data suggest that Trappsol® Cyclo™ overcomes the NPC1 defect by...
